Floatz logo

AMONAFIDE

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Antisoma ResearchSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Secondary Acute Myeloid Leukemia (Secondary AML, sAML) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

AMONAFIDE is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
prostate cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →